Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
Background. Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic options ranging from discontinuation of immunos...
Saved in:
Main Authors: | Ryan S. Chiang, Ashton A. Connor, Brant A. Inman, Wen-Chi Foo, David N. Howell, John F. Madden, Matthew J. Ellis, Aparna S. Rege, Michael R. Harrison |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Urology |
Online Access: | http://dx.doi.org/10.1155/2020/8881841 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
by: Ernest Choy, et al.
Published: (2023-01-01) -
Update on the Treatment of Metastatic Urothelial Carcinoma
by: Nedal Bukhari, et al.
Published: (2018-01-01) -
Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01) -
Urothelial Carcinoma of the Bladder Metastatic to Bone Marrow Presenting as Isolated Thrombocytopenia
by: Robert C. Chan, et al.
Published: (2007-01-01) -
Plasmacytoid Urothelial Carcinoma of the Bladder Metastatic to the Stomach: A Case Report
by: Philippe Nabbout, et al.
Published: (2012-01-01)